Invitrogen to Exclusively Market Biocon's Pharma-Grade Insulin Worldwide | GenomeWeb
NEW YORK (GenomeWeb News) — Invitrogen will exclusively market pharmaceutical-grade insulin made by Indian biotech Biocon to global cell-culture customers, Invitrogen said yesterday.
 
Invitrogen said Biocon’s insulin is equivalent to others used for cell-culture bio-manufacturing and in delaying apoptosis in mammalian cell cultures.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.